Alpha Fusion

Executive Summary

Alpha Fusion is a Japanese biotechnology company pioneering targeted alpha therapy (TAT) using Astatine-211 (²¹¹At) for oncology. Founded in 2020 and currently in Phase 1, the company focuses on radioiodine-refractory thyroid cancer and prostate cancer. Its technology delivers high-energy alpha particles with a short range, precisely destroying cancer cells while sparing healthy tissue. Leveraging Japan's expertise in radiopharmaceuticals and Astatine-211 production, Alpha Fusion aims to address unmet needs in hard-to-treat cancers. As a private, early-stage company with 10-50 employees, it is positioned to capitalize on growing interest in TAT, though no financial details or specific milestones are disclosed. The company's platform could offer significant advantages over conventional therapies if clinical data proves positive.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 trial for Astatine-211 TAT in thyroid cancer40% success
• TBDPartnership or collaboration with a larger radiopharma company for co-development20% success
• Q2 2026Presentation of preclinical or early clinical data at a major oncology conference50% success